| Pair Name | Bufalin, Osimertinib | ||
| Phytochemical Name | Bufalin (PubChem CID: 9547215 ) | ||
| Anticancer drug Name | Osimertinib (PubChem CID: 71496458 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Bufalin, Osimertinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | MCL1 | hsa4170 |
| In Vitro Model | HCC827 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_2063 |
| PC-9 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_B260 | |
| Result | Our study suggests that bufalin eliminates resistance to osimertinib by inhibiting Ku70-mediated MCL-1 overexpression, indicating that a combination of osimertinib and bufalin could be an effective additional treatment to overcome acquired resistance to osimertinib in NSCLC cells. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. Toxicol Appl Pharmacol. 2019 Sep 15;379:114662. doi: 10.1016/j.taap.2019.114662. | Click |
